Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012

Biologicals

Volumn 40, Issue 6, 2012, Pages 517-527

  Kay, Jonathan ^a   Feagan, Brian G ^b   Guirguis, Micheal S ^c   Keystone, Edward C ^d   Klein, Agnes V ^e   Lubiniecki, Anthony S ^f   Mould, Diane R ^g   Nyarko, Kwasi A ^e   Ridgway, Anthony A G ^e   Trudeau, Maureen E ^h   Wang, Jian ^e  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c Alberta Blue Cross   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e HEALTH CANADA   (Canada)

^f Janssen Pharmaceutical Companies of Johnson and Johnson   (United States)

^g Projections Research Inc   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biosimilars; Follow on protein products; Interchangeability; Similar biological medicinal products; Subsequent entry biologics; Substitution

Indexed keywords

BIOSIMILAR AGENT; SUBSEQUENT ENTRY BIOLOGIC; UNCLASSIFIED DRUG;

ARTICLE; CANADA; CLINICAL PRACTICE; CONSENSUS; DRUG APPROVAL; DRUG CONTROL; DRUG INDICATION; DRUG MANUFACTURE; DRUG SURVEILLANCE PROGRAM; EDUCATION PROGRAM; HEALTH CANADA; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH INSURANCE; PHYSICIAN; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

BIOLOGICAL AGENTS; CANADA; DRUG APPROVAL; DRUG INDUSTRY;

EID: 84868366831     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2012.09.010     Document Type: Article

References (44)

1. Reichert J.M. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany. MAbs 2011, 3:223-240.
2. Wadhwa M., Kang H.N., Knezevic I., Thorpe R., Griffiths E. WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24-26 August, 2010. Biologicals 2011, 39:349-357.
3. Committee for Medicinal Products for Human Use, European Medicines Agency Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. EMEA/CHMP/BWP/49348/2005 2006, [accessed 03.07.12]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf.
4. Committee for Medicinal Products for Human Use, European Medicines Agency Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005 2006, [accessed 03.07.12]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf.
5. World Health Organization Guidelines on evaluation of similar biotherapeutic products (SBP) 2009, [accessed 18.08.12]. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.
6. Health Products and Food Branch, Health Canada Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs) 2010, [accessed 03.07.12]. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.pdf.
7. Food and Drug Administration Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product (draft) 2012, [accessed 03.07.12]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
8. Food and Drug Administration Guidance for industry: quality considerations in demonstrating biosimilarity to a reference product (draft) 2012, [accessed 03.07.12]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf.
9. Health Canada Summary basis of decision for OMNITROPE 2009, [accessed 18.08.12]. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2009_omnitrope_113380-eng.pdf.
10. Klein A.V. The first subsequent entry biologic authorized for market in Canada: the story of Omnitrope, a recombinant human growth hormone. Biologicals 2011, 39:278-281.
11. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther 2011, 13:112.
12. Scheinberg M.A., Kay J. The advent of biosimilar therapies in rheumatology-" O Brave New World". Nat Rev Rheumatol 2012, 8:430-436.
13. Committee for Medicinal Products for Human Use, European Medicines Agency Guideline on similar biological medicinal products containing monoclonal antibodies (draft). EMA/CHMP/BMWP/403543/2010 2010, [accessed 03.07.12]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/11/WC500099361.pdf.
14. Casadevall N., Dupuy E., Molho-Sabatier P., Tobelem G., Varet B., Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996, 334:630-633.
15. Boven K., Stryker S., Knight J., Thomas A., van Regenmortel M., Kemeny D.M., et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005, 67:2346-2353.
16. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Specifications: test procedures and acceptance criteria for biotechnological/biological products: Q6B 1999, [accessed 03.07.12]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf.
17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Comparability of biotechnological/biological products subject to changes in their manufacturing process, Q5E 2004, [accessed 03.07.12]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf.
18. 2012 APEC Harmonization Center Biosimilar Workshop. (April 3-5, 2012) Seoul, Korea. [accessed 03.07.12]. http://www.apec-ahc.org/contents/page.jsp%3fmcode%3d3021001.
19. Burg J, Sellinger KH, Haselbeck A, Koll H. Erythropoietin with high specific activity, European Patent. PCT/EP/98/07876.
20. Storring P.L., Tiplady R.J., Gaines Das R.E., Stenning B.E., Lamikanra A., Rafferty B., et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998, 100:79-89.
21. Skibeli V., Nissen-Lie G., Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001, 98:3626-3634.
22. Schellekens H. Biosimilar epoetins: how similar are they?. Eur J Hosp Pharm Sci 2004, 3:43-47.
23. Jiang H., Wu S.L., Karger B.L., Hancock W.S. Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator. Anal Chem 2010, 82:6154-6162.
24. Xie H., Chakraborty A., Ahn J., Yu Y.Q., Dakshinamoorthy D.P., Gilar M., et al. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2010, 2:379-394.
25. European Medicines Agency Questions and answers on recommendation for refusal of marketing application for Alpheon 2006, [accessed 18.08.12]. http://www.ema.europa.eu/docs/enGB/documentlibrary/SummaryofopinionInitialauthorisation/human/000585/WC500017451.pdf.
26. European Medicines Agency Questions and answers on the withdrawal of the marketing authorization application for insulin human rapid Marvel, insulin human long Marvel, insulin human 30/70 mix Marvel 2008, [accessed 18.08.12]. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500015341.pdf.
27. Schiestl M., Stangler T., Torella C., Cepeljnik T., Toll H., Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011, 29:310-312.
28. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
29. Karmiris K., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterol 2009, 137:1628-1640.
30. Sandborn W., Rutgeerts P., Reinishch W., Mantzaris G., Kornbluth A., Rachmilewetz D., et al. SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Am J Gastroenterol 2008, 103:1117. [Late-breaking abstract 29].
31. Afif W., Loftus E.V., Faubion W.A., Kane S.V., Bruining D.H., Hanson K.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
32. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144:865-876.
33. Nesbitt A., Fossati G., Bergin M., Stephens P., Stephens S., Foulkes R., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007, 13:1323-1332.
34. Weir N., Athwal D., Brown D., Foulkes R., Kollias G., Nesbitt A., et al. A new generation of high-affinity humanized PEGylated Fab fragment anti-tumor necrosis factor-α monoclonal antibodies. Therapy 2006, 3:535-545.
35. Data on file. Janssen Biotech Inc.
36. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549. ACCENT I Study Group.
37. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921-926.
38. Lecluse L.L., Driessen R.J., Spuls P.I., de Jong E.M., Stapel S.O., van Doorn M.B., et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010, 146:127-132.
39. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010, 69:817-821.
40. Mould D.R., Baumann A., Kuhlmann J., Keating M.J., Weitman S., Hillmen P., et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007, 64:278-291.
41. Kapel N., Meillet D., Favennec L., Magne D., Raichvarg D., Gobert J.G. Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis. Eur J Clin Chem Clin Biochem 1992, 30:197-202.
42. Custodio A., Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol 2012, [Epub ahead of print].
43. Government of Alberta Alberta health and wellness drug benefit list 1 April 2012, [accessed 03.07.12]. https://www.ab.bluecross.ca/dbl/pdfs/ahwdbl_april_list.pdf.
44. Program on International Nonproprietary Names (INN), World Health Organization Guidelines on the use of international nonproprietary names (INNs) for pharmaceutical substances 2007, [accessed 20.08.12]. http://whqlibdoc.who.int/hq/1997/WHO_PHARM_S_NOM_1570.pdf.